NasdaqGS:STOKBiotechs
Biogen Partnership and Zorevunersen Data Could Be a Game Changer for Stoke Therapeutics (STOK)
Biogen Inc. and Stoke Therapeutics recently announced plans to present new clinical data for zorevunersen, an investigational treatment for Dravet syndrome, at the 36th International Epilepsy Congress in Lisbon.
This investigational therapy features a unique mechanism aimed at addressing the underlying genetic cause of Dravet syndrome, targeting an area of high unmet medical need.
We'll explore how the upcoming clinical data presentations for zorevunersen may shape Stoke Therapeutics'...